Progression-free survival was improved with little overall survival benefit.
Uveal melanoma (UM) is a form of melanoma genetically, biologically, and clinically distinct from cutaneous melanoma (CM). Unlike CM, UMs appear to be driven by mutations in GNAQ and GNA11 rather than BRAF. Currently, there are no agents that are known to target GNAQ/GNA11. In an earlier study (Cancer Discovery July 2013), the MEK inhibitor selumetinib lengthened progression-free survival in patients with metastatic UM. Now, these authors report results of a randomized phase II trial of selumetinib versus chemotherapy.
From August 2010 through December 2013, 101 patients with metastatic uveal melanoma were randomized to receive 75 mg of selumetinib orally twice a day or chemotherapy (oral temozolomide or intravenous dacarbazine). Median prog…
Reviewing Author
DisclosuresConsultant / advisory board Lubax; WorldCare Clinical
EquityLubax
Grant / Research support NIH; Department of Defense; American Skin Association; Piramal
Editorial boardsBritish Journal of Dermatology; Journal of the American Academy of Dermatology; Journal of Investigative Dermatology
Leadership positions in professional societies American Academy of Dermatology (Chair, Skin Cancer and Melanoma Committee); American Board of Dermatology (Director)
DisclosuresConsultant / advisory board Lubax; WorldCare Clinical
EquityLubax
Grant / Research support NIH; Department of Defense; American Skin Association; Piramal
Editorial boardsBritish Journal of Dermatology; Journal of the American Academy of Dermatology; Journal of Investigative Dermatology
Leadership positions in professional societies American Academy of Dermatology (Chair, Skin Cancer and Melanoma Committee); American Board of Dermatology (Director)